Alice Zhang (Verge Genomics)

Eli Lil­ly makes mod­est bet on 'all-in-hu­man' dis­cov­ery out­fit for ALS drugs, deep­en­ing bid in pre­ci­sion neu­rol­o­gy

For years, Big Phar­ma has re­treat­ed from neu­rol­o­gy amid a se­ries of high-pro­file fail­ures in the big-tick­et in­di­ca­tions such as Alzheimer’s and ALS. But the tide has turned in re­cent years, and big drug­mak­ers like Eli Lil­ly have dou­bled down on their in­vest­ments in the space.

Now, look­ing to crack a new path to “pre­ci­sion neu­rol­o­gy,” Lil­ly is putting its name be­hind a ge­nomics play­er aim­ing for a nov­el path to neu­ro­log­i­cal dis­ease ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.